AU2001239001A1 - Method for producing vaccines containing a heat-treated mixture consisting of at least one antigen and of at least one adjuvant - Google Patents

Method for producing vaccines containing a heat-treated mixture consisting of at least one antigen and of at least one adjuvant

Info

Publication number
AU2001239001A1
AU2001239001A1 AU2001239001A AU3900101A AU2001239001A1 AU 2001239001 A1 AU2001239001 A1 AU 2001239001A1 AU 2001239001 A AU2001239001 A AU 2001239001A AU 3900101 A AU3900101 A AU 3900101A AU 2001239001 A1 AU2001239001 A1 AU 2001239001A1
Authority
AU
Australia
Prior art keywords
adjuvant
antigen
heat
mixture consisting
vaccines containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001239001A
Inventor
Helmut Eckert
Hans Loibner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Igeneon Krebs-Immuntherapie Forschungs- und Entwicklungs-GmbH
Original Assignee
Igeneon Krebs-Immuntherapie Forschungs- und Entwicklungs-GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igeneon Krebs-Immuntherapie Forschungs- und Entwicklungs-GmbH filed Critical Igeneon Krebs-Immuntherapie Forschungs- und Entwicklungs-GmbH
Publication of AU2001239001A1 publication Critical patent/AU2001239001A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A method of preparing a vaccine formulation comprising at least one antigen and at least one adjuvant is described, which method is characterized in that at least one antigen is mixed with at least one adjuvant and the mixture subsequently is heat-treated at a temperature of at least 80° C. for a period of time of at least 5 minutes.
AU2001239001A 2000-03-21 2001-03-21 Method for producing vaccines containing a heat-treated mixture consisting of at least one antigen and of at least one adjuvant Abandoned AU2001239001A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT472/2000 2000-03-21
AT0047200A AT410172B (en) 2000-03-21 2000-03-21 METHOD FOR PRODUCING VACCINE FORMULATION
PCT/AT2001/000080 WO2001070264A1 (en) 2000-03-21 2001-03-21 Method for producing vaccines containing a heat-treated mixture consisting of at least one antigen and of at least one adjuvant

Publications (1)

Publication Number Publication Date
AU2001239001A1 true AU2001239001A1 (en) 2001-10-03

Family

ID=3674774

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001239001A Abandoned AU2001239001A1 (en) 2000-03-21 2001-03-21 Method for producing vaccines containing a heat-treated mixture consisting of at least one antigen and of at least one adjuvant

Country Status (9)

Country Link
US (1) US7615226B2 (en)
EP (1) EP1265631B1 (en)
AT (2) AT410172B (en)
AU (1) AU2001239001A1 (en)
CA (1) CA2404108C (en)
DE (1) DE50109757D1 (en)
ES (1) ES2263597T3 (en)
MX (1) MXPA02009161A (en)
WO (1) WO2001070264A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030092145A1 (en) * 2000-08-24 2003-05-15 Vic Jira Viral vaccine composition, process, and methods of use
US9974847B2 (en) * 2000-08-24 2018-05-22 Immunitor USA, Inc. Treatment and prevention of tuberculosis
AT504160A1 (en) * 2006-09-11 2008-03-15 Ralf Dr Kircheis USING A MULTICOMPONENT TUMOR VARC

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3876763A (en) * 1970-12-29 1975-04-08 Shionogi & Co Infectious coryza infectious bronchitis and newcastle disease vaccines and production thereof
US5370871A (en) * 1983-01-24 1994-12-06 The Johns Hopkins University Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
NL8401066A (en) * 1984-04-04 1985-11-01 Stichting Centraal Lab PROCESS FOR PREPARING PREPARATIONS INCREASING HUMORAL AND CELLULAR IMMUNE ACTIVITY
NL8401173A (en) 1984-04-12 1985-11-01 Philips Nv FLAME PROTECTION CIRCUIT.
US6818222B1 (en) * 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US6274143B1 (en) 1997-06-13 2001-08-14 Malaya Chatterjee Methods of delaying development of HMFG-associated tumors using anti-idiotype antibody 11D10
US6270723B1 (en) * 1998-06-15 2001-08-07 Bbi Bioseq, Inc. Rapid cryobaric sterilization and vaccine preparation
NZ512722A (en) * 1999-01-13 2003-07-25 Igeneon Krebs Immuntherapie Use of Ep-CAM antibodies for anticancer vaccination
AT409086B (en) * 1999-11-16 2002-05-27 Igeneon Krebs Immuntherapie NEW USE OF ANTIBODIES AS VACCINE

Also Published As

Publication number Publication date
EP1265631B1 (en) 2006-05-10
EP1265631A1 (en) 2002-12-18
CA2404108C (en) 2012-01-03
US20030143221A1 (en) 2003-07-31
ES2263597T3 (en) 2006-12-16
ATE325622T1 (en) 2006-06-15
CA2404108A1 (en) 2001-09-27
DE50109757D1 (en) 2006-06-14
ATA4722000A (en) 2002-07-15
WO2001070264A1 (en) 2001-09-27
US7615226B2 (en) 2009-11-10
MXPA02009161A (en) 2004-08-12
AT410172B (en) 2003-02-25

Similar Documents

Publication Publication Date Title
WO2000057917A3 (en) Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
HK1044484A1 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide.
HUP0402067A2 (en) Vaccines
GB9817052D0 (en) Vaccine
WO1997049423A3 (en) Liposomal influenza vaccine composition and method
GB0130123D0 (en) Outer membrane vesicle vaccine and its preparation
IL150602A (en) Proteosome influenza vaccine, method for preparing such and use thereof
EP2368575A3 (en) Dry formulation for transcutaneous immunization
IL154913A0 (en) Composition comprising immunogenic microparticles
AU2002338832A1 (en) Vaccine
PL1635863T3 (en) Compositions to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
WO2005037190A3 (en) Multiplex vaccines
AU7980794A (en) Methods and compositions for microencapsulation of antigens for use as vaccines
AU4324996A (en) Novel cyclodextrin-derivatives and methods for the preparation thereof
AU2457100A (en) Enhancement of bactericidal activity of neisseria antigens with oligonucleotidescontaining cg motifs
BR0111834A (en) Adjuvant and immunogenic compositions, and method for eliciting an immune response to an antigen
IL139601A0 (en) Compositions and methods of modulating an immune response to an antigen
AU2001239001A1 (en) Method for producing vaccines containing a heat-treated mixture consisting of at least one antigen and of at least one adjuvant
WO2002034287A3 (en) Therapeutic vaccine formulations containing chitosan
WO2001070265A3 (en) Lipopeptide adjuvants
WO1999002132A3 (en) Use of submicron oil-in-water emulsions with dna vaccines
EP1905449A3 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
ATE353226T1 (en) ADJUVANT COMPOSITION CONTAINING FHA OR AN FHA FRAGMENT IN FREE FORM
WO2002036160A3 (en) Method for obtaining antigenic structures enhancing specific cross reactivity
WO2002030458A8 (en) Yersinia adhesion protein as vaccine adjuvant